In one paragraphArticle in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
5 authors.
Hailey SeibertHailey Seibert, BS, School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH; Hanna Kakish, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH; Jeremy S. Bordeaux, MD, MPH, Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; Luke D. Rothermel, MD, MPH, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; and Richard S. Hoehn, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH.ORCID 0000-0003-3545-3766 Hanna KakishHailey Seibert, BS, School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH; Hanna Kakish, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH; Jeremy S. Bordeaux, MD, MPH, Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; Luke D. Rothermel, MD, MPH, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; and Richard S. Hoehn, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH.ORCID 0000-0002-1282-5443 Jeremy S BordeauxHailey Seibert, BS, School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH; Hanna Kakish, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH; Jeremy S. Bordeaux, MD, MPH, Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; Luke D. Rothermel, MD, MPH, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; and Richard S. Hoehn, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH.ORCID 0000-0002-7010-7730 Luke D RothermelHailey Seibert, BS, School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH; Hanna Kakish, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH; Jeremy S. Bordeaux, MD, MPH, Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; Luke D. Rothermel, MD, MPH, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; and Richard S. Hoehn, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH.ORCID 0000-0001-5700-8028 Richard S HoehnHailey Seibert, BS, School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH; Hanna Kakish, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH; Jeremy S. Bordeaux, MD, MPH, Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; Luke D. Rothermel, MD, MPH, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH; and Richard S. Hoehn, MD, Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH.ORCID 0000-0003-1455-6758 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Socioeconomic factors influence the survival of patients with early stage melanoma and thus should be accounted for in prognostication tools.
Indexed as
MelanomaSocioeconomic FactorsFemaleHumansMaleNeoplasm StagingSelection BiasSkin Neoplasms
What OpenQuestion holds
Textmetadata
Read underepoch 390